Quince Therapeutics, Inc. is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases.

Quince has dosed the first patient and is actively enrolling participants for our global the Phase 3 NEAT study. Patients with A-T interested in participating can learn more about the NEAT study criteria and locations by visiting Clinicaltrials.gov here and Clinical Trials Information System here.

David Geffen School of Medicine at the University of California, Los Angeles & UCLA Health

Jul 24, 2023 · Under the terms of the acquisition transaction, EryDel will operate as a wholly owned subsidiary of Quince Therapeutics with plans to retain EryDel’s corporate and manufacturing presence in Italy. The integrated company will be led by Dirk Thye, M.D., Quince’s

Jan 27, 2025 · EryDex leverages Quince’s proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells.

Feb 5, 2025 · SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 5, 2025-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will ...

Oct 30, 2024 · The Investor Relations website contains information about Quince Therapeutics's business for stockholders, potential investors, and financial analysts.

EryKit is a CE marked medical device. It provides the essential single-use components for loading human red blood cells (RBCs) with variety of therapeutics, ranging from small to large molecules, as well as biologics, by using the RCL.

Aug 1, 2022 · The launch of Quince Therapeutics marks a strategic shift in focus as the company prioritizes the clinical development of its highly differentiated bone-targeting drug platform and lead precision bone growth molecule, NOV004, to address major, unmet medical needs across multiple skeletal therapeutic indications.

Quince is dedicated to harnessing the power of a patient’s own biology to deliver innovative and life-changing therapeutics to those living with rare diseases. Our proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform is an innovative drug/device combination that uses an automated process to encapsulate a drug ...